Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2023-08-15 00:00:00 ET · period of report 2023-08-11 · accession 0001765581-23-000090 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-15 | 2023-08-14 | JAZZ | Smith Mark Douglas | Dir | S - Sale | $138.16 | -1,241 | 7,305 | -15% | -$171.5K | |
| 2023-08-15 | 2023-08-11 | JAZZ | Smith Mark Douglas | Dir | A - Grant | $0.00 | +3,075 | 8,546 | +56% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-08-14 | S | D | 1,241 | $138.16 | 7,305 | D | — | — | (F3) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.63 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| 2 | Common | Ordinary Shares | 2023-08-11 | A | A | 3,075 | $0.00 | 8,546 | D | — | — |